The USA300 strain of MRSA was put in the spotlight recently in a study published online by The Annals of Internal Medicine. Results showed that at one Boston area health clinic monitored in the study, 97% of patients infected with MRSA had the USA300 strain. The AIM study was led by Dr. Binh Diep who stressed the urgent need for prevention of these potentially deadly infections.
"Once this reaches the general population, it will be truly unstoppable," said Diep. "That's why we're trying to spread the message of prevention."
Researchers conducting the Oregon State University study also focused on prevention by testing products that are commonly used to prevent various infections in cuts and scrapes, rather than testing more expensive prescription antibiotics that attempt to kill the superbug after a severe infection takes hold.
The study was recently presented at a meeting of the American Society of Health-System Pharmacists by Dr. David Bearden, a specialist in infectious diseases and an author of the study. Dr. George P. Allen joined Bearden and Christensen as the third author.
"Staphaseptic remained bactericidal for 24 hours, which surprised me," said Christensen. "Usually you see an initial kill, which is followed by the bacteria growing again. But Staphaseptic blunted this regrowth and suppressed the bacteria, showing killing for up to 24 hours."
According to Bearden, USA300 is being passionately studied for a reason. "USA300 has become the predominant strain in severe community-acquired skin infections. The strain is more virulent and infects individuals who are otherwise healthy, something that earlier hospital strains of MRSA did not."
A copy of the original OSU Time Kill study can be viewed by following
this link http://www.teclabsinc.com/press_docs/MRSA_
|SOURCE Tec Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved